Related Experiment Videos
Optimizing images of acute deep-vein thrombosis using technetium-99m-apcitide.
R F Carretta1, P V Streek, F L Weiland
1Sutter-Roseville Medical Center, Roseville, California 95661, USA. rcarretta@aol.com
Journal of Nuclear Medicine Technology
|January 26, 2000
Summary
This study introduces 99mTc-apcitide, a novel radiopharmaceutical for imaging acute venous thrombosis. It details technologist preparation, administration, positioning, and imaging parameters for effective deep-vein thrombosis detection.
Area of Science:
- Nuclear Medicine
- Radiopharmacology
Background:
- Venous thromboembolism is a significant clinical challenge.
- Accurate and timely diagnosis of deep-vein thrombosis (DVT) is crucial for effective patient management.
Purpose of the Study:
- To introduce nuclear medicine technologists to 99mTc-apcitide, a new radiopharmaceutical for imaging acute venous thrombosis.
- To provide essential information for the safe and effective use of 99mTc-apcitide in clinical practice.
- To highlight the diagnostic value of 99mTc-apcitide in detecting acute deep-vein thrombosis.
Main Methods:
- The paper outlines patient preparation protocols for 99mTc-apcitide administration.
- It specifies the recommended dosage of 99mTc-apcitide for imaging acute venous thrombosis.
- Guidance on optimal patient positioning and gamma camera acquisition parameters is provided.
Main Results:
- Clinical cases demonstrate the whole-body distribution of 99mTc-apcitide.
- The diagnostic utility of 99mTc-apcitide in identifying acute deep-vein thrombosis is illustrated.
- High-quality imaging parameters are discussed for accurate diagnosis.
Conclusions:
- 99mTc-apcitide is a valuable new radiopharmaceutical for imaging acute venous thrombosis.
- Proper patient preparation, dosing, positioning, and acquisition parameters are key to successful imaging.
- This agent aids in the detection of acute deep-vein thrombosis.